Davita (DVA) Stock News

Tolion Health AI (DVA) appointed Gregory J. Moore, MD, PhD, to its board on January 6, 2026, strengthening clinical, AI, regulatory, and global growth expertise.

Dr. Moore brings experience leading health and life-sciences teams at Microsoft and Google, board service at DaVita and Fortive, and academic and clinical credentials. Tolion highlighted its 2025 US launch of Tolion Brain Coach on the Apple App Store, recent fundraising, and US/Europe infrastructure growth. Near-term priorities include user growth, Apple Health interoperability, an Android release, Garmin integration, and partnerships with labs, health plans, and specialty providers.

DaVita (NYSE: DVA) named Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, effective Dec. 11, 2025. Both executives bring more than a decade of experience at DaVita and will lead people, strategy, and innovation efforts—Phillips will oversee DaVita Venture Group and corporate strategy. The appointments emphasize a people-first approach and a focus on technology-driven care transformation.

As of Sept. 30, 2025, DaVita served approximately 293,200 patients at 3,247 outpatient centers worldwide, underscoring the scale behind the leadership shift.

DaVita (NYSE: DVA) said its chief financial officer, Joel Ackerman, will take part in a fireside chat at the Wolfe Research Healthcare Conference on Monday, November 17, 2025 at 11:20 am ET.

Investors can watch a live webcast via Wolfe Research with free registration. As of September 30, 2025, DaVita served approximately 293,200 patients at 3,247 outpatient dialysis centers—2,662 in the United States and 585 across 14 other countries.

The company describes itself as a comprehensive kidney care provider focused on clinical quality and transforming care delivery.

DaVita (NYSE: DVA) will present six new studies at ASN Kidney Week 2025 in Houston (Nov 5–9), including an oral presentation linking GLP‑1 receptor agonist use with improved hospitalization rates in patients with end‑stage kidney disease. The studies cover dialysis modalities, middle‑molecule clearance, transplant access, and end‑of‑life care.

DaVita highlights ongoing R&D into advanced dialysis therapies and middle‑molecule removal and will staff booth #702 at the George R. Brown Convention Center. As of Sept 30, 2025, DaVita served approximately 293,200 patients across 3,247 outpatient dialysis centers (2,662 U.S.; 585 in 14 other countries).

DaVita (NYSE: DVA) reported results for the quarter ended September 30, 2025: consolidated revenue $3.420B, operating income $506M and adjusted operating income $517M. Diluted EPS was $2.04 and adjusted diluted EPS was $2.51. Operating cash flow was $842M and free cash flow was $604M. The company refinanced its Term Loan B-1 with a new $1.9B Term Loan B-2 and repurchased 3.3M shares for $465M (avg $140.67).

Notable items: Mozarc equity losses $51.3M (including $25.9M impairment), cybersecurity-related charges of ~$11.7M in Q3 ($24.2M YTD), and normalized non-acquired treatment growth of (0.6)%. Updated 2025 guidance: adjusted operating income $2,035–$2,135M, adjusted diluted EPS $10.35–$11.15, free cash flow $1,000–$1,250M.

DaVita (NYSE: DVA) announced two U.S. initiatives—MODEL and MEMOIRS—launching Oct 20, 2025 to evaluate middle-molecule clearance in patients with kidney failure.

MODEL is a quality-improvement survival review and MEMOIRS is a prospective cohort survey of patient-reported outcomes comparing medium cut-off versus high-flux dialyzers. Together they will include about 9,000 adults with end-stage kidney disease over the next two years, aiming to generate first-of-its-kind U.S. evidence to inform dialysis care standards.

DaVita (NYSE: DVA) will report third quarter 2025 results and host a conference call on Wednesday, October 29, 2025. Results will be released after market close the same day, and the call starts at 5:00 p.m. Eastern Time. The call will be webcast and accessible on DaVita's investor relations webpage.

Dial-in details: domestic 877-918-6630, international 517-308-9042; participants should provide the password "Earnings" and their name/company. A webcast replay will be available at investors.davita.com; there will be no telephone replay.

Operational snapshot: as of June 30, 2025, DaVita served ~283,100 patients at 3,175 outpatient dialysis centers (2,662 U.S.; 513 in 13 other countries).

DaVita (NYSE:DVA), a leading kidney care provider, celebrates 25 years of its research division DaVita Clinical Research (DCR). The research arm has conducted over 500 clinical trials across 250+ research sites, with 8,900+ participants in the last 5 years. DCR has contributed to every FDA-approved ESKD drug and published 180 manuscripts and 520 research abstracts.

Notable achievements include participation in COVID-19 vaccine trials, revising nephrology standards for anemia management, and implementing decentralized recruitment services in 2024 to increase diverse patient participation. The company currently serves 283,100 patients at 3,175 outpatient dialysis centers globally, with 2,662 centers in the US and 513 centers across 13 other countries.

DaVita Inc. (NYSE: DVA) reported its Q2 2025 financial results with consolidated revenues of $3.380 billion and operating income of $538 million. The company achieved diluted earnings per share of $2.58 and adjusted diluted EPS of $2.95.

Key highlights include $324 million in operating cash flow, issuance of $1.0 billion of 6.75% senior notes, and repurchase of 3.1 million shares at an average price of $144.00. The company experienced a cybersecurity incident resulting in $13.5 million in charges. DaVita served approximately 283,100 patients across 3,175 outpatient dialysis centers globally.

For 2025 guidance, DaVita projects adjusted operating income of $2,010-$2,160 million and adjusted diluted EPS of $10.20-$11.30.